3/12
03:09 pm
lxrx
Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.
Low
Report
Lexicon Pharmaceuticals (LXRX) was given a new $6.00 price target by HC Wainwright.
3/11
08:00 am
lxrx
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
Medium
Report
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
3/10
11:02 am
lxrx
Lexicon Pharmaceuticals (LXRX) had its price target raised by Citigroup Inc. from $2.10 to $2.30. They now have a "buy" rating on the stock.
Low
Report
Lexicon Pharmaceuticals (LXRX) had its price target raised by Citigroup Inc. from $2.10 to $2.30. They now have a "buy" rating on the stock.
3/5
12:51 pm
lxrx
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Neutral
Report
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/5
11:44 am
lxrx
Lexicon Pharmaceuticals (LXRX) had its price target raised by HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.
Medium
Report
Lexicon Pharmaceuticals (LXRX) had its price target raised by HC Wainwright from $4.00 to $6.00. They now have a "buy" rating on the stock.
3/5
07:26 am
lxrx
Lexicon: Q4 Earnings Snapshot [Yahoo! Finance]
Medium
Report
Lexicon: Q4 Earnings Snapshot [Yahoo! Finance]
3/5
07:18 am
lxrx
Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M [Seeking Alpha]
Medium
Report
Lexicon Pharmaceuticals GAAP EPS of -$0.04 beats by $0.03, revenue of $5.49M beats by $2.35M [Seeking Alpha]
3/5
07:15 am
lxrx
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates [Yahoo! Finance]
3/5
06:59 am
lxrx
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
Low
Report
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
3/3
04:34 pm
lxrx
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences [Yahoo! Finance]
Low
Report
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences [Yahoo! Finance]
3/3
04:01 pm
lxrx
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
Low
Report
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
2/26
08:30 am
lxrx
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
Low
Report
Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026
2/23
01:21 am
lxrx
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials [Yahoo! Finance]
Low
Report
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting With Fine Tuned Targets And Trials [Yahoo! Finance]
2/6
05:17 pm
lxrx
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
Medium
Report
Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
1/30
02:50 am
lxrx
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
High
Report
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement
1/29
04:31 pm
lxrx
Lexicon Announces Proposed Public Offering of Common Stock
High
Report
Lexicon Announces Proposed Public Offering of Common Stock
1/27
08:33 am
lxrx
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
Medium
Report
How A Reset Price Target Is Reframing The Story For Lexicon Pharmaceuticals (LXRX) [Yahoo! Finance]
1/23
08:43 am
lxrx
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary [Yahoo! Finance]
1/23
08:30 am
lxrx
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
Medium
Report
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary
1/22
03:21 pm
lxrx
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward [Seeking Alpha]
Low
Report
Lexicon Pharmaceuticals: 'Hold' As FDA Feedback Allows Pilavapadin For DPNP To Go Forward [Seeking Alpha]
1/21
08:30 am
lxrx
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
High
Report
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain
1/12
07:30 am
lxrx
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference
1/9
07:03 pm
lxrx
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” [Yahoo! Finance]
Neutral
Report
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” [Yahoo! Finance]
1/9
08:30 am
lxrx
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
Low
Report
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”
1/7
08:30 am
lxrx
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference